CY1105060T1 - Νεες σουλφαμιδες και η χρηση τους σαν ανταγωνιστικων ληπτων ενδοθηλινης - Google Patents

Νεες σουλφαμιδες και η χρηση τους σαν ανταγωνιστικων ληπτων ενδοθηλινης

Info

Publication number
CY1105060T1
CY1105060T1 CY20061100879T CY061100879T CY1105060T1 CY 1105060 T1 CY1105060 T1 CY 1105060T1 CY 20061100879 T CY20061100879 T CY 20061100879T CY 061100879 T CY061100879 T CY 061100879T CY 1105060 T1 CY1105060 T1 CY 1105060T1
Authority
CY
Cyprus
Prior art keywords
endothilin
acceptors
competitive
sulfamides
novel
Prior art date
Application number
CY20061100879T
Other languages
Greek (el)
English (en)
Inventor
Martin Bolli
Christoph Boss
Walter Fischli
Martine Clozel
Thomas Weller
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8164206&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1105060(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of CY1105060T1 publication Critical patent/CY1105060T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/56—One oxygen atom and one sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/60—Three or more oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CY20061100879T 2000-12-18 2006-06-27 Νεες σουλφαμιδες και η χρηση τους σαν ανταγωνιστικων ληπτων ενδοθηλινης CY1105060T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP0012890 2000-12-18
PCT/EP2001/014182 WO2002053557A1 (en) 2000-12-18 2001-12-04 Novel sulfamides and their use as endothelin receptor antagonists

Publications (1)

Publication Number Publication Date
CY1105060T1 true CY1105060T1 (el) 2010-03-03

Family

ID=8164206

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20061100879T CY1105060T1 (el) 2000-12-18 2006-06-27 Νεες σουλφαμιδες και η χρηση τους σαν ανταγωνιστικων ληπτων ενδοθηλινης
CY2014017C CY2014017I1 (el) 2000-12-18 2014-04-11 Νεες σουλφαμιδες και η χρηση τους σαν ανταγωνιστικων ληπτων ενδοθηλινης

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY2014017C CY2014017I1 (el) 2000-12-18 2014-04-11 Νεες σουλφαμιδες και η χρηση τους σαν ανταγωνιστικων ληπτων ενδοθηλινης

Country Status (27)

Country Link
US (2) US7094781B2 (instruction)
EP (2) EP1693372A1 (instruction)
JP (1) JP4245130B2 (instruction)
KR (1) KR100819668B1 (instruction)
CN (1) CN100432070C (instruction)
AR (1) AR035610A1 (instruction)
AT (1) ATE323079T1 (instruction)
AU (1) AU2002227984B8 (instruction)
BE (1) BE2014C019I2 (instruction)
BR (1) BRPI0116237B8 (instruction)
CA (1) CA2431675C (instruction)
CY (2) CY1105060T1 (instruction)
DE (1) DE60118782T2 (instruction)
DK (1) DK1345920T3 (instruction)
ES (1) ES2260318T3 (instruction)
FR (1) FR14C0017I2 (instruction)
HU (1) HU229403B1 (instruction)
IL (2) IL155805A0 (instruction)
LU (1) LU92381I2 (instruction)
MX (1) MXPA03004780A (instruction)
MY (1) MY129150A (instruction)
NL (1) NL300672I2 (instruction)
NO (2) NO324952B1 (instruction)
NZ (1) NZ525614A (instruction)
PT (1) PT1345920E (instruction)
WO (1) WO2002053557A1 (instruction)
ZA (1) ZA200303695B (instruction)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1345920T3 (da) * 2000-12-18 2006-08-14 Actelion Pharmaceuticals Ltd Hidtil ukendte sulfamider og anvendelse deraf som endothelinreceptorantagonister
WO2003049739A1 (en) * 2001-12-07 2003-06-19 Vertex Pharmaceuticals, Inc. Pyrimidine-based compounds useful as gsk-3 inhibitors
CA2507334C (en) * 2002-12-02 2013-05-07 Actelion Pharmaceuticals Ltd. Pyrimidine-sulfamides and their use as endothelian receptor antagonist
AU2005229331B2 (en) 2004-03-05 2011-10-13 F. Hoffmann-La Roche Ag Diaminopyrimidines as P2X3 and P2X2/3 antagonists
UA90269C2 (ru) 2004-04-02 2010-04-26 Мицубиси Танабе Фарма Корпорейшн Тетрагидрохинолиновые производные и способ их получения
TW200628467A (en) 2004-11-11 2006-08-16 Actelion Pharmaceuticals Ltd Novel sulfamides
RU2436787C2 (ru) 2005-07-29 2011-12-20 Тиботек Фармасьютикалз Лтд. Макроциклические ингибиторы вируса гепатита с
MY139923A (en) 2005-07-29 2009-11-30 Tibotec Pharm Ltd Macrocylic inhibitors of hepatitis c virus
CN101253159B (zh) 2005-09-01 2011-12-07 弗·哈夫曼-拉罗切有限公司 作为p2x3和p2x2/3调节剂的二氨基嘧啶类化合物
WO2007025901A1 (en) 2005-09-01 2007-03-08 F. Hoffmann-La Roche Ag Diaminopyrimidines as p2x3 and p2x2/3 modulators
CN101296907B (zh) 2005-09-01 2013-03-27 弗·哈夫曼-拉罗切有限公司 作为p2x3和p2x2/3调节剂的二氨基嘧啶类
PT1928409E (pt) * 2005-09-12 2012-11-27 Actelion Pharmaceuticals Ltd Composição farmacêutica estável que compreende uma pirimidina-sulfamida
AR062501A1 (es) * 2006-08-29 2008-11-12 Actelion Pharmaceuticals Ltd Composiciones terapeuticas
US7983024B2 (en) 2007-04-24 2011-07-19 Littelfuse, Inc. Fuse card system for automotive circuit protection
MX2010001837A (es) * 2007-08-17 2010-03-10 Actelion Pharmaceuticals Ltd Derivados de 4-pirimidinasulfamida.
EP2199283A1 (en) 2007-09-27 2010-06-23 Kowa Company, Ltd. Prophylactic and/or therapeutic agent for anemia, comprising tetrahydroquinoline compound as active ingredient
US8541433B2 (en) 2008-02-20 2013-09-24 Actelion Pharmaceuticals, Ltd. Combination comprising macitentan and paclitaxel for treating multi-drug resistant ovarian cancer
EP3360873A1 (en) * 2008-07-08 2018-08-15 Incyte Holdings Corporation 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase
LT2315587T (lt) * 2008-08-13 2018-01-10 Actelion Pharmaceuticals Ltd. Terapinės kompozicijos, turinčios macitentano
US8791090B2 (en) 2009-03-31 2014-07-29 Kowa Company, Ltd. Prophylactic and/or therapeutic agent for anemia comprising tetrahydroquinoline compound as active ingredient
NZ598078A (en) 2009-08-10 2013-07-26 Univ Texas Treatment of brain metastases with macitentan in combination with paclitacel and/or temozolomide and/or radiotherapy
CN102753177A (zh) 2009-08-17 2012-10-24 纪念斯隆-凯特琳癌症中心 热休克蛋白结合化合物、组合物以及其制备和使用方法
WO2011078143A1 (ja) * 2009-12-22 2011-06-30 塩野義製薬株式会社 ピリミジン誘導体およびそれらを含有する医薬組成物
AU2012213036A1 (en) 2011-02-04 2013-09-19 Actelion Pharmaceuticals Ltd Combinations comprising macitentan for the treatment of glioblastoma multiforme
WO2014140059A1 (en) * 2013-03-15 2014-09-18 F. Hoffmann-La Roche Ag ARYL SULFAMIDE AND SULFAMATE DERIVATIVES AS RORc MODULATORS
AR095727A1 (es) * 2013-03-27 2015-11-04 Actelion Pharmaceuticals Ltd Preparación de intermediarios de pirimidina
DE14721256T1 (de) 2013-04-22 2017-03-16 Sandoz Ag Pharmazeutische zusammensetzungen mit kristallinem macitentan
CN104411691B (zh) * 2013-06-14 2016-05-25 杭州普晒医药科技有限公司 马西替坦晶体及其制备方法、其药物组合物和用途
AR096865A1 (es) * 2013-07-12 2016-02-03 Actelion Pharmaceuticals Ltd Proceso para la preparación de un intermediario de pirimidina
CN103724281A (zh) * 2013-12-03 2014-04-16 镇江圣安医药有限公司 N-[5-（4-溴苯基）-6-[2-[（5-溴-2-嘧啶基）氧基]乙氧基]-4-嘧啶基]-n′-丙基磺酰胺的新型衍生物及其应用
EP2907811A1 (en) * 2014-02-14 2015-08-19 Actelion Pharmaceuticals Ltd. Process for manufacturing pyrimidine sulfamide derivatives
CN103819411A (zh) * 2014-03-14 2014-05-28 成都克莱蒙医药科技有限公司 一种马西替坦中间体新的制备方法
ES2774975T3 (es) 2014-05-13 2020-07-23 Memorial Sloan Kettering Cancer Center Moduladores de hsp70 y métodos para fabricar y utilizar el mismo
US20170158645A1 (en) * 2014-07-15 2017-06-08 Olon S.P.A. Amorphous form and new crystalline forms of macitentan
CN104447572A (zh) * 2014-12-15 2015-03-25 南京艾德凯腾生物医药有限责任公司 一种马西替坦的制备方法
WO2016203489A1 (en) 2015-06-15 2016-12-22 Megafine Pharma (P) Ltd. Process for the preparation of macitentan and intermediates thereof
ZA201605808B (en) 2015-08-26 2017-08-30 Cipla Ltd Process for preparing an endothelin receptor antagonist
CN105388244B (zh) * 2015-12-10 2017-03-08 合肥久诺医药科技有限公司 一种马西替坦有关物质的高效液相色谱分析方法
CN105461639B (zh) * 2015-12-10 2018-03-09 合肥久诺医药科技有限公司 一种高纯度马西替坦的精制方法
WO2017191565A1 (en) * 2016-05-04 2017-11-09 Shilpa Medicare Limited Process for preparation of macitentan
CN107868055B (zh) * 2016-09-28 2020-02-07 普济生物科技（台州）有限公司 一种马西替坦的制备方法
CN106478522A (zh) * 2016-10-11 2017-03-08 合肥久诺医药科技有限公司 一种马西替坦杂质标准品的制备方法
CN106478520B (zh) * 2016-10-11 2018-09-11 合肥久诺医药科技有限公司 一种马西替坦杂质标准品的合成方法
SI3658140T1 (sl) 2017-02-27 2025-08-29 Idorsia Pharmaceuticals Ltd Kombinacije aprocitentana z nadaljnjimi učinkovinami za zdravljenje rezistentne hipertenzije
WO2018185013A1 (en) 2017-04-03 2018-10-11 Syngenta Participations Ag Microbiocidal oxadiazole derivatives
CN107141238A (zh) * 2017-06-16 2017-09-08 吴宁怡 一种马西替坦中间体的制备方法
PL3719013T3 (pl) * 2017-11-21 2023-05-08 Wuxi Biocity Biopharmaceutics Co., Ltd. Pochodna sulfamidowa pirymidyny oraz sposób jej wytwarzania i zastosowanie medyczne
WO2019106066A1 (en) 2017-11-30 2019-06-06 Idorsia Pharmaceuticals Ltd Combination of a 4-pyrimidinesulfamide derivative with an sglt-2 inhibitor for the treatment of endothelin related diseases
CN108653292B (zh) * 2018-07-03 2019-05-24 中国人民解放军总医院 一种化合物在治疗或预防高原病中的用途
CN108997223B (zh) * 2018-08-09 2020-06-30 浙江先锋科技股份有限公司 5-(4-溴苯基)-4，6-二氯嘧啶的制备方法
CN109232546B (zh) 2018-09-25 2020-09-04 中国人民解放军总医院 一种嘧啶磺酰胺类衍生物的医药用途
PT3897646T (pt) 2018-12-21 2024-07-08 Actelion Pharmaceuticals Ltd Macitentano para tratamento de hipertensão arterial pulmonar
TW202042818A (zh) 2019-01-25 2020-12-01 瑞士商艾克泰聯製藥有限公司 用於治療慢性血栓性肺高血壓之醫藥組成物
TW202103703A (zh) 2019-04-05 2021-02-01 瑞士商艾克泰聯製藥有限公司 用於治療門脈肺高血壓之方法
CN118480033A (zh) * 2019-05-22 2024-08-13 无锡智康弘义生物科技有限公司 一种嘧啶磺酰胺类化合物的晶型及其制备方法
DK3993777T3 (da) 2019-07-05 2024-09-16 Tecnimede Sociedade Tecnico Medicinal Sa Komprimerede macitentansammensætninger, fremgangsmåder og anvendelser deraf
IL293271A (en) 2019-11-29 2022-07-01 Actelion Pharmaceuticals Ltd Methods of treating pulmonary arterial hypertension
WO2022258796A1 (en) 2021-06-11 2022-12-15 Actelion Pharmaceuticals Ltd Dispersible tablet for oral administration
EP4154873A1 (en) 2021-09-22 2023-03-29 Sanovel Ilac Sanayi Ve Ticaret A.S. The tablet comprising macitentan
KR20250016196A (ko) 2022-05-22 2025-02-03 이도르시아 파마슈티컬스 리미티드 고혈압의 치료를 위한 아프로시텐탄
AU2023275935A1 (en) 2022-05-25 2025-01-09 Idorsia Pharmaceuticals Ltd Crystalline forms of sodium (5-(4-bromophenyl)-6-(2-((5-bromopyrimidin-2-yl)oxy)ethoxy)pyrimidin-4-yl)(sulfamoyl)amide
KR20250100728A (ko) 2022-11-07 2025-07-03 액테리온 파마슈티칼 리미티드 폐 동맥 고혈압 치료를 위한 마시텐탄과 타다라필의 조합물
WO2025102245A1 (zh) * 2023-11-14 2025-05-22 浙江天宇药业股份有限公司 一种双重内皮素受体拮抗剂阿普昔腾坦的合成方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2801584A1 (de) 1978-01-14 1979-07-19 Bayer Ag Halogensubstituierte pyrimidin (2)yl-thiono-thiol-phosphor(phosphon)- saeureester, verfahren zu ihrer herstellung und ihre verwendung als insektizide und akarizide
US5132373A (en) * 1990-08-13 1992-07-21 General Electric Company Ortho ester-capped polyphenylene ethers and copolymers prepared therefrom
RU2086544C1 (ru) 1991-06-13 1997-08-10 Хоффманн-Ля Рош АГ Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина
US5324796A (en) * 1992-12-02 1994-06-28 General Electric Company Polyarylene sulfide and epoxy-functionalized siloxane blends
TW394761B (en) 1993-06-28 2000-06-21 Hoffmann La Roche Novel Sulfonylamino Pyrimidines
US5523204A (en) 1993-12-10 1996-06-04 Becton Dickinson And Company Detection of nucleic acids in cells by strand displacement amplification
WO1996016963A1 (de) * 1994-11-25 1996-06-06 F. Hoffmann-La Roche Ag Sulfonamide und deren verwendung als heilmittel
TW313568B (instruction) * 1994-12-20 1997-08-21 Hoffmann La Roche
US5739333A (en) 1995-05-16 1998-04-14 Tanabe Seiyaku Co., Ltd. Sulfonamide derivative and process for preparing the same
WO1997022595A1 (fr) 1995-12-20 1997-06-26 Yamanouchi Pharmaceutical Co., Ltd. Derives arylethenesulfonamide et composition de medicaments renfermant ces derives
TWI284642B (en) * 1999-01-18 2007-08-01 Hoffmann La Roche Novel heterocyclic sulfonamides
IL143935A (en) * 1999-09-03 2005-08-31 Actelion Pharmaceuticals Ltd Bis-sulfonamides
IL149529A0 (en) * 1999-12-22 2002-11-10 Actelion Pharmaceuticals Ltd Butyne diol derivatives
AU2001263850A1 (en) 2000-04-20 2001-11-07 Actelion Pharmaceuticals Ltd Pyrimidine-sulfonamides having endothelin-antagonist activity
WO2001081338A1 (en) 2000-04-25 2001-11-01 Actelion Pharmaceuticals Ltd Substituted sulfonylaminopyrimidines
DK1345920T3 (da) * 2000-12-18 2006-08-14 Actelion Pharmaceuticals Ltd Hidtil ukendte sulfamider og anvendelse deraf som endothelinreceptorantagonister

Also Published As

Publication number Publication date
MXPA03004780A (es) 2004-05-21
BRPI0116237B1 (pt) 2016-08-09
AU2002227984B2 (en) 2006-12-07
DE60118782T2 (de) 2007-01-25
EP1345920A1 (en) 2003-09-24
AR035610A1 (es) 2004-06-16
BRPI0116237B8 (pt) 2021-05-25
BR0116237A (pt) 2003-09-30
US7285549B2 (en) 2007-10-23
CN1524079A (zh) 2004-08-25
CA2431675C (en) 2011-11-08
KR100819668B1 (ko) 2008-04-04
ES2260318T3 (es) 2006-11-01
KR20030066713A (ko) 2003-08-09
CY2014017I2 (el) 2015-12-09
EP1693372A1 (en) 2006-08-23
HUP0301654A2 (en) 2007-03-28
JP2004517855A (ja) 2004-06-17
FR14C0017I2 (fr) 2014-11-14
US7094781B2 (en) 2006-08-22
LU92381I2 (fr) 2014-04-28
HU229403B1 (en) 2013-12-30
CA2431675A1 (en) 2002-07-11
ATE323079T1 (de) 2006-04-15
BE2014C019I2 (instruction) 2021-01-29
AU2002227984B8 (en) 2007-01-04
NO20032699L (no) 2003-06-13
IL155805A (en) 2009-02-11
CY2014017I1 (el) 2015-12-09
DK1345920T3 (da) 2006-08-14
HUP0301654A3 (en) 2007-08-28
AU2002227984A1 (en) 2002-07-16
NO20032699D0 (no) 2003-06-13
EP1345920B1 (en) 2006-04-12
US20060178365A1 (en) 2006-08-10
NO324952B1 (no) 2008-01-14
NL300672I2 (instruction) 2016-10-11
WO2002053557A1 (en) 2002-07-11
MY129150A (en) 2007-03-30
PT1345920E (pt) 2006-08-31
FR14C0017I1 (instruction) 2021-08-27
IL155805A0 (en) 2003-12-23
US20040077670A1 (en) 2004-04-22
ZA200303695B (en) 2004-08-13
NZ525614A (en) 2005-03-24
CN100432070C (zh) 2008-11-12
NO2014014I2 (no) 2015-08-31
DE60118782D1 (de) 2006-05-24
JP4245130B2 (ja) 2009-03-25

Similar Documents

Publication Publication Date Title
CY1105060T1 (el) Νεες σουλφαμιδες και η χρηση τους σαν ανταγωνιστικων ληπτων ενδοθηλινης
ATE286500T1 (de) 1,2,3,4-tetrahydroisochinolin-derivate
CY1104993T1 (el) 4-(πιπεριδυλ- και πυρρολιδινυλ-αλκυλ-ουρεϊδο)-κινολινες ως ανταγωνιστες του υποδοχεα ουροτασινης ii
NO20034230D0 (no) 1,2,3,4-tetrahydroisokinolin-derivater som urotensin II reseptor-antagonister
NO20032905D0 (no) Nye benzodiazepiner og beslektede heterocykliske derivater som er anvendelige som orexinreseptorantagonister
NO20051102L (no) Sulfonylamino-eddiksyre-derivater
BG66084B1 (bg) Циклопентаноиндоли, състави,съдържащи такива съединения и използването им
IS6658A (is) Ný efnasambönd
ATE435210T1 (de) Tetrahydroisochinolylacetamidderivate zur verwendung als orexinrezeptorantagonisten
CY1111698T1 (el) Συνδυασμος που περιλαμβανει εναν ανταγωνιστη υποδοχεα ατ1 και εναν ενισχυτη εκκρισης ινσουλινης ή εναν ευαισθητοποιητη ινσουλινης
ATE486587T1 (de) Formulierungen zur oralen verabreichung von wirkstoffen
TR200200066T2 (tr) Migrenin tedavisi için seçici iGluR5 reseptör antagonistleri
TR200200359T2 (tr) Cgrp Antagonist'lerinin ve cgrp-release (Gevşeme)-Engelleyici Menopoza Bağlı Deri Kızarıklıklarında Kullanılması
BR9909486A (pt) Compostos calcilìticos
MXPA04001252A (es) Nuevos heterociclos benzo-fusionados como antagonistas de endotelina.
NO20052520L (no) Nye sulfamider
WO2002024665A8 (en) Arylalkane-sulfonamides having endothelin-antagonist activity
MXPA03000430A (es) Nuevas arileteno-sulfonamidas.
TR200103090T2 (tr) Integrın reseptör antagonistleri
MXPA02006250A (es) Derivados de butino diol.
SE0004780D0 (sv) Novel compunds
BR0107179A (pt) Amidinas cìclicas e acìclicas e composições farmacêuticas contendo as mesmas para uso como agentes de ligação de receptor de progesterona
BR0102864A (pt) Compostos, composições farmacêuticas, processos para a fabricação de compostos e de composições farmacêuticas, e, uso de um ou mais compostos